Improvement in OCD symptoms associated with serotoninergic psychedelics: a retrospective online survey
In a retrospective online survey of 174 participants, classic serotoninergic psychedelics were the only substances reported to reduce OCD symptoms. Reduction correlated with the intensity of acute effects (itself linked to dose), persisted variably from weeks to months with no clear predictors, and larger/more persistent improvements predicted subsequent intake frequency.
Abstract
A renewed interest in the use of psychedelics for treating obsessive compulsive disorder (OCD) has emerged in the last 20 years. But pre-clinical and clinical evidence remain scarce, and little is known about the factor determining the magnitude and persistence of the therapeutic effect. We therefore designed a retrospective online survey to explore, in the general population using psychoactive drugs, their impact on OCD symptoms. We also assessed the attitude of the participants towards the substance in term of frequency of intakes. In a sample of 174 participants, classic psychedelics were reported as the only substances effective at reducing OCD symptoms. In classic psychedelics users, symptoms reduction was associated with the intensity of acute effects, itself correlated to the dose. Reports on the persistence of the therapeutic effect varied from weeks to months, but we could not find any predicting factor. Finally, the occurrence and frequency of subsequent intakes, which seemed to be limited in our sample, were predicted by the magnitude and persistence of the therapeutic effect, respectively. Our observations support the hypothesis of classic psychedelics efficacy in reducing OCD symptoms but a careful evaluation of the persistence of this effect is still needed.
Research Summary of 'Improvement in OCD symptoms associated with serotoninergic psychedelics: a retrospective online survey'
Introduction
OCD is a chronic, often disabling psychiatric disorder featuring intrusive obsessions and repetitive compulsions. Standard treatments combine cognitive and behavioural therapy with high-dose selective serotonin reuptake inhibitors (SSRIs), but many patients have incomplete response, long delays to benefit and 30–40% non-response. This gap has renewed interest in alternative approaches, including classic serotoninergic psychedelics such as LSD and psilocybin, but clinical and preclinical evidence for their efficacy in OCD is limited, long-term outcomes are poorly characterised, and placebo/expectation effects are difficult to rule out in open or uncontrolled work. Buot and colleagues therefore conducted a retrospective, anonymous online survey in people with OCD symptoms to identify which psychoactive substances users perceived as changing their OCD, to examine whether any improvement related to features of the acute subjective experience (intensity, pleasantness), mindset and setting, and to document the occurrence and frequency of subsequent intakes. The survey targeted a broad set of substances and sought to explore determinants of both the magnitude and persistence of any self-reported therapeutic effects in a real-world sample.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Create a free account to open full-text PDFs.
Study Details
- Study Typeindividual
- Journal
- Topics
- Author
- APA Citation
Buot, A., Pallares, C., Oganesyan, A., Dauré, C., Bonnelle, V., Burguière, E., Dos Santos, J. F. A., N’Diaye, K., Ljuslin, M., Smith, P., Verroust, V., Wyplosz, B., Morgiève, M., & Mallet, L. (2023). Improvement in OCD symptoms associated with serotoninergic psychedelics: a retrospective online survey. Scientific Reports, 13(1). https://doi.org/10.1038/s41598-023-39812-0
References (23)
Papers cited by this study that are also in Blossom
Lugo-Radillo, A., Cortes-Lopez, J. L. · Journal of Psychoactive Drugs (2020)
Moreton, S. G., Burden-Hill, A., Menzies, R. E. · Clinical Psychologist (2022)
King, C., Nichols, D. E. · Nature Reviews Neuroscience (2013)
Agin-Liebes, G. I., Lancelotta, R., Uthaug, M. V. et al. · ACS Pharmacology and Translational Science (2021)
Carbonaro, T. M., Bradstreet, M. P., Barrett, F. S. et al. · Journal of Psychopharmacology (2016)
Garcia-Romeu, A., Davis, A. K., Fire Erowid et al. · Journal of Psychopharmacology (2019)
Johnson, M. W., Garcia-Romeu, A., Johnson, P. S. et al. · Journal of Psychopharmacology (2017)
Pisano, V. D., Putnam, N. P., Kramer, H. M. et al. · Journal of Psychopharmacology (2017)
Hartogsohn, I. · Drug Science Policy and Law (2017)
Tylš, F., Páleníček, T., Horacek, J. · European Neuropsychopharmacology (2013)
Show all 23 referencesShow fewer
Haijen, E. C. H. M., Kaelen, M., Roseman, L. et al. · Frontiers in Pharmacology (2018)
Fantegrossi, W. E., Murnane, K. S., Reissig, C. J. · Biochemical Pharmacology (2007)
Halberstadt, A. L., Geyer, M. A. · Neuropharmacology (2011)
Studerus, E., Gamma, A., Kometer, M. et al. · PLOS ONE (2012)
Carhart-Harris, R. L., Giribaldi, B., Watts, R. et al. · New England Journal of Medicine (2021)
Bogenschutz, M. P., Ross, S., Bhatt, S. R. et al. · JAMA Psychiatry (2022)
Dolder, P. C., Schmid, Y., Steuer, A. E. et al. · Clinical Pharmacokinetics (2017)
Wilcox, C. E. · Journal of Psychoactive Drugs (2014)
Delgado, P. L., Moreno, F. A. · Journal of Psychoactive Drugs (1998)
Carhart-Harris, R. L., Bolstridge, &. M., Day, C. M. J. et al. · Psychopharmacology (2017)
Ly, C., Greb, A. C., Cameron, L. P. et al. · Cell Reports (2018)
Shao, L-X,, Liao, C., Gregg, I. et al. · Neuron (2021)
Vargas, M. V., Dunlap, L. E., Dong, C. et al. · Science (2023)
Cited By (4)
Papers in Blossom that reference this study
Moreno, F. A., Allen, K. E., Wiegand, C. B. et al. · Journal of Psychopharmacology (2026)
Ching, T. H. W., Stahnke, B., Shnayder, S. et al. · Frontiers in Psychiatry (2025)
Ertl, N., Ashraf, I., Azizi, L. et al. · Biorxiv (2025)
Gordon, A. R., Carrithers, B. M., Pagni, B. A. et al. · Research Square (2024)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.